CA3261035A1 - Pharmaceutical composition comprising kras g12d inhibitor - Google Patents

Pharmaceutical composition comprising kras g12d inhibitor

Info

Publication number
CA3261035A1
CA3261035A1 CA3261035A CA3261035A CA3261035A1 CA 3261035 A1 CA3261035 A1 CA 3261035A1 CA 3261035 A CA3261035 A CA 3261035A CA 3261035 A CA3261035 A CA 3261035A CA 3261035 A1 CA3261035 A1 CA 3261035A1
Authority
CA
Canada
Prior art keywords
cancer
pharmaceutical composition
composition according
ammonium
liposome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3261035A
Other languages
French (fr)
Inventor
Ruilin SHA
Ziqing DUAN
Haifeng Wang
Xinyong Tong
Pingping Wang
Biao Feng
Bin Wang
Original Assignee
Shanghai Hengrui Pharmaceutical Co Ltd
Jiangsu Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Hengrui Pharmaceutical Co Ltd, Jiangsu Hengrui Pharmaceutical Co Ltd filed Critical Shanghai Hengrui Pharmaceutical Co Ltd
Publication of CA3261035A1 publication Critical patent/CA3261035A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present disclosure relates to a pharmaceutical composition comprising a KRAS G12D inhibitor. In particular, the present disclosure relates to a pharmaceutical composition, comprising a compound represented by formula I or a pharmaceutically acceptable salt thereof, and a lipid. The pharmaceutical composition can be better applied clinically.

Claims (16)

  1. 37 CLAIMS 1. A pharmaceutical composition, comprising a compound of formula I or a pharmaceutically acceptable salt thereof and a lipid, .
  2. 2. The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition is a liposome.
  3. 3. The pharmaceutical composition according to claim 1 or 2, wherein the lipid comprises at least one phospholipid, and the phospholipid is preferably dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), dimyristoylphosphatidylcholine (DMPC), 1-palmitoyl-2-linoleoyl-sn-glycero-3- phosphatidylcholine (PLPC), dioleoylphosphatidylcholine (DOPC), dierucoylphosphatidylcholine (DEPC), egg yolk phosphatidylcholine (EPC), dilauroylphosphatidylcholine (DLPC), hydrogenated soy phosphatidylcholine (HSPC), 1- myristoyl-2-palmitoylphosphatidylcholine (MPPC), 1-palmitoyl-2- myristoylphosphatidylcholine (PMPC), 1-palmitoyl-2-stearoylphosphatidylcholine (PSPC), 1-stearoyl-2-palmitoylphosphatidylcholine (SPPC), palmitoyloleoylphosphatidylcholine (POPC), lysophosphatidylcholine, dilinoleoylphosphatidylcholine, distearoylphosphatidylethanolamine (DSPE), dimyristoylphosphatidylethanolamine (DMPE), dipalmitoylphosphatidylethanolamine (DPPE), dioleoylphosphatidylglycerol (DOPG), dimyristoylphosphatidylglycerol (DMPG), distearoylphosphatidylglycerol (DSPG), dipalmitoylglycerophosphoglycerol (DPPG), dipalmitoylphosphatidylserine (DPPS), 1,2-dioleoyl-sn-glycero-3-phosphatidylserine (DOPS), dimyristoylphosphatidylserine (DMPS), distearoylphosphatidylserine (DSPS), dipalmitoylphosphatidic acid (DPPA), 1,2-dioleoyl-sn-glycero-3-phosphatidic acid (DOPA), dimyristoylphosphatidic acid (DMPA), distearoylphosphatidic acid (DSPA), dipalmitoylphosphatidylinositol (DPPI), 1,2-dioleoyl-sn-glycero-3-phosphatidylinositol (DOPI), dimyristoylphosphatidylinositol (DMPI), distearoylphosphatidylinositol (DSPI), and derivatives thereof; more preferably dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC),38 dierucoylphosphatidylcholine (DEPC), dilauroylphosphatidylcholine (DLPC), hydrogenated soy phosphatidylcholine (HSPC), distearoylphosphatidylethanolamine (DSPE), and dimyristoylphosphatidylcholine (DMPC), and polyethylene glycol-modified derivatives thereof; most preferably hydrogenated soy phosphatidylcholine (HSPC) and polyethylene glycol 2000-distearoylphosphatidylethanolamine (mPEG2000-DSPE).
  4. 4. The pharmaceutical composition according to any one of claims 1-3, wherein the phospholipid has a molar percentage selected from the group consisting of 10%-80%, preferably 30%-70%, relative to a total amount of a lipid mixture.
  5. 5. The pharmaceutical composition according to any one of claims 1-4, wherein the lipid further comprises a steroid, preferably cholesterol.
  6. 6. The pharmaceutical composition according to claim 5, wherein the steroid has a molar percentage selected from the group consisting of 0.1%-90%, preferably 10%-80%, and more preferably 20%-70%, relative to the total amount of the lipid mixture.
  7. 7. The pharmaceutical composition according to any one of claims 1-6, further comprising a trapping agent, wherein the trapping agent is preferably a sulfate, a sulfite, a gluconate, a phosphate, a hydrogen phosphate, a molybdate, a carbonate, and a nitrate, and is more preferably ammonium sulfate, ammonium phosphate, ammonium molybdate, ammonium sucrose octasulfate, triethylammonium sucrose octasulfate, copper gluconate, ethylammonium sulfate, ammonium ethylenediaminetetraacetate, ammonium chloride, ammonium hydroxide, ammonium acetate, dextran ammonium sulfate, or triethyldextran ammonium sulfate, and combinations thereof.
  8. 8. The pharmaceutical composition according to any one of claims 1-7, wherein an inner aqueous phase of the liposome further comprises at least one pH adjuster, and the pH adjuster is preferably sodium hydroxide, hydrochloric acid, ammonia water, phosphoric acid, malic acid, histidine, or triethanolamine.
  9. 9. The pharmaceutical composition according to any one of claims 1-8, wherein the compound of formula I or the pharmaceutically acceptable salt thereof has a concentration selected from the group consisting of 0.01-100 mg/mL, preferably 0.05-10 mg/mL.
  10. 10. The pharmaceutical composition according to any one of claims 1-9, wherein an outer aqueous phase of the liposome comprises one or more selected from the group consisting of a sugar, an electrolyte, and an amino acid or a salt thereof, preferably sodium chloride and histidine or a salt thereof.39
  11. 11. A lyophilized composition, wherein the lyophilized composition is obtained by lyophilizing or spray-drying the pharmaceutical composition according to any one of claims 1-10.
  12. 12. A lyophilized composition, wherein the lyophilized composition is capable of being reconstituted to give the pharmaceutical composition according to any one of claims 1-10.
  13. 13. A reconstituted solution, wherein the reconstituted solution is obtained by reconstituting the lyophilized composition according to claim 11.
  14. 14. A liposome, comprising a compound of formula I or a pharmaceutically acceptable salt thereof, .
  15. 15. A method for preparing the pharmaceutical composition according to any one of claims 2-10 or the liposome according to claim 14, comprising steps of preparing a blank liposome, and introducing the compound of formula I or the pharmaceutically acceptable salt thereof into an inner aqueous phase of the blank liposome.
  16. 16. Use of the pharmaceutical composition according to any one of claims 1-10, the lyophilized composition according to claim 11 or 12 or the reconstituted solution according to claim 13 or the liposome according to claim 14 in the preparation of a medicament for treating a disease or disorder, wherein the disease or disorder is preferably a cancer, and is more preferably selected from the group consisting of brain cancer, thyroid cancer, head and neck cancer, nasopharyngeal cancer, laryngeal cancer, oral cancer, salivary gland cancer, esophageal cancer, gastric cancer, lung cancer, liver cancer, renal cancer, pancreatic cancer, gallbladder cancer, bile duct cancer, colorectal cancer, small intestine cancer, gastrointestinal stromal tumor, urothelial cancer, urinary tract cancer, bladder cancer, breast cancer, vaginal cancer, ovarian cancer, endometrial cancer, cervical cancer, fallopian tube cancer, testicular cancer, prostate cancer, hemangioma, leukemia, lymphoma, myeloma,40 skin cancer, lipoma, bone cancer, soft tissue sarcoma, neurofibroma, neuroglioma, neuroblastoma, and glioblastoma.
CA3261035A 2022-07-29 2023-07-28 Pharmaceutical composition comprising kras g12d inhibitor Pending CA3261035A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202210909959 2022-07-29
CN202210909959.1 2022-07-29
CN202211642769 2022-12-20
CN202211642769.4 2022-12-20
PCT/CN2023/109901 WO2024022507A1 (en) 2022-07-29 2023-07-28 Pharmaceutical composition comprising kras g12d inhibitor

Publications (1)

Publication Number Publication Date
CA3261035A1 true CA3261035A1 (en) 2025-04-04

Family

ID=89705462

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3261035A Pending CA3261035A1 (en) 2022-07-29 2023-07-28 Pharmaceutical composition comprising kras g12d inhibitor

Country Status (9)

Country Link
EP (1) EP4563151A4 (en)
JP (1) JP2025524799A (en)
KR (1) KR20250037564A (en)
CN (1) CN119384279A (en)
AU (1) AU2023314335A1 (en)
CA (1) CA3261035A1 (en)
MX (1) MX2025001036A (en)
TW (1) TW202408536A (en)
WO (1) WO2024022507A1 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202315626A (en) * 2021-08-31 2023-04-16 大陸商勁方醫藥科技(上海)有限公司 Pyrimidine-fused cyclic compound and preparation method and use thereof
CN119365467A (en) 2022-05-19 2025-01-24 基因泰克公司 Aza-tetracyclic oxazapine compounds and uses thereof
AU2023320565A1 (en) 2022-08-05 2025-01-23 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
CN121487738A (en) 2023-03-30 2026-02-06 锐新医药公司 Compositions for inducing RAS GTP hydrolysis and their uses
KR20260019479A (en) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Combination therapy for RAS-related diseases or disorders
CN121889155A (en) 2023-08-07 2026-04-17 锐新医药公司 RMC-6291 for the treatment of RAS protein-related diseases or disorders
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9968570B2 (en) * 2013-01-14 2018-05-15 Chemo-Enhanced Llc Compositions and methods for treating cancer
WO2018206539A1 (en) * 2017-05-11 2018-11-15 Astrazeneca Ab Heteroaryl compounds that inhibit g12c mutant ras proteins
CN114615981B (en) 2019-08-29 2024-04-12 米拉蒂治疗股份有限公司 KRAS G12D inhibitors
CN112745335B (en) * 2019-10-30 2024-08-30 武汉誉祥医药科技有限公司 Tri-heterocyclic compound and application thereof
WO2021106231A1 (en) * 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation
WO2021203768A1 (en) * 2020-04-08 2021-10-14 江苏恒瑞医药股份有限公司 Pyrimido dicyclo derivative, preparation method therefor and use thereof in medicine
WO2022017339A1 (en) * 2020-07-20 2022-01-27 江苏恒瑞医药股份有限公司 Fused pyridazine derivative, preparation method therefor and pharmaceutical use thereof
US20240199644A1 (en) * 2021-03-07 2024-06-20 Jacobio Pharmaceuticals Co., Ltd. Fused Ring Derivatives Useful as KRAS G12D Inhibitors
CN117043167A (en) * 2021-03-17 2023-11-10 劲方医药科技(上海)有限公司 Pyrimidinocyclic compounds and their preparation methods and uses
MX2023015533A (en) * 2021-06-21 2024-01-23 Jiangsu Hengrui Pharmaceuticals Co Ltd Fused tetracyclic compound, preparation method therefor and application thereof in medicine.
CN117677624A (en) * 2021-07-19 2024-03-08 上海艾力斯医药科技股份有限公司 Novel Pyridopyrimidine Derivatives
CA3226720A1 (en) * 2021-07-23 2023-01-26 Suzhou Zanrong Pharma Limited Kras g12d inhibitors and uses thereof

Also Published As

Publication number Publication date
AU2023314335A1 (en) 2025-02-27
EP4563151A4 (en) 2025-11-05
KR20250037564A (en) 2025-03-17
TW202408536A (en) 2024-03-01
CN119384279A (en) 2025-01-28
EP4563151A1 (en) 2025-06-04
JP2025524799A (en) 2025-08-01
WO2024022507A1 (en) 2024-02-01
MX2025001036A (en) 2025-03-07

Similar Documents

Publication Publication Date Title
JP5981214B2 (en) Compositions and methods for the treatment of lymphoma
JP4874547B2 (en) Drug loading method to liposome by gradient
US20040228909A1 (en) Compositions and methods for treating lymphoma
US12059499B2 (en) Liposome loading
US20040071768A1 (en) Compositions and methods for treating cancer
AU2023314335A1 (en) Pharmaceutical composition comprising kras g12d inhibitor
IL278079B1 (en) Inhalable liposomal sustained release composition for use in treating pulmonary diseases
EP2968146B1 (en) Controlled drug release liposome composition
CA2184834A1 (en) Liposome preparation
WO2014047116A1 (en) Encapsulating liposomes
JP4950890B2 (en) Delivery of iron to animals
RU2025103683A (en) PHARMACEUTICAL COMPOSITION CONTAINING KRAS G12D INHIBITOR
US7244450B2 (en) Compositions and methods for treating lymphoma
CA3032687C (en) Liposomal composition containing mild acidic active agent
WO2021239134A1 (en) Liposome containing ethylenediamine tetraacetic acid or salt thereof and eribulin or pharmaceutically acceptable salt thereof
WO2025235614A1 (en) Liposome loading with polyanions
RU2021132189A (en) PHARMACEUTICAL COMPOSITION OF A WEAK ACID DRUG AND METHODS OF APPLICATION
HK1125833A (en) Compositions and methods for treating lymphoma
HK1255538B (en) Liposome loading
HK1160032B (en) Combinations of a liposomal water-soluble camptothecin with cetuximab or bevacizumab
HK1160032A (en) Combinations of a liposomal water-soluble camptothecin with cetuximab or bevacizumab

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20241231

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241231

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED

Effective date: 20241231

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20250404

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250404

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250404

Q12 Application published

Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION PUBLISHED (OPEN TO PUBLIC INSPECTION)

Effective date: 20250404

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250404

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REGISTER A DOCUMENT REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250404

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250610

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250610

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260528

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260602

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260603